RFA
CORT icon

Reilly Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

Reilly Financial Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,000
Closed -$112K – 904
2019
Q2 		$112K Buy
+10,000
New +$111K 0.01% 233

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Reilly Financial Advisors's CORT Position: Q3 2019 in Review

Reilly Financial Advisors sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 10,000 shares — an estimated $112K sold.

Reilly Financial Advisors first reported a position in CORT in Q2 2019 and held it in 1 quarter. The position peaked at $112K in Q2 2019. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

  • Reilly Financial Advisors reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Reilly Financial Advisors sold 10,000 Corcept Therapeutics shares in Q3 2019, an estimated $112K.
  • Reilly Financial Advisors first reported a position in Corcept Therapeutics in Q2 2019 and held it in 1 quarter.
  • Reilly Financial Advisors's Corcept Therapeutics position peaked at $112K in Q2 2019.
  • 193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Reilly Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.